{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:18:57Z","timestamp":1747156737742,"version":"3.40.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.canrad.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T12:23:51Z","timestamp":1732191831000},"page":"657-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study"],"prefix":"10.1016","volume":"28","author":[{"given":"Carolinne","family":"Brassart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Coutte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Wallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Benyoucef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajer","family":"Mnif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00ebl","family":"Barthoulot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-7309","authenticated-orcid":false,"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2024.05.005_bib0150","unstructured":"Anon. Cancer today. Data visualization tools for exploring the global cancer burden in 2022. Lyon: International Agency for Research on Cancer; \u00a92024. URL: http:\/\/gco.iarc.fr\/today\/home (accessed February 8, 2022)."},{"year":"2019","series-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018 - Volume 1\u00a0: tumeurs solides\u00a0: \u00e9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim","author":"Defossez","key":"10.1016\/j.canrad.2024.05.005_bib0155"},{"key":"10.1016\/j.canrad.2024.05.005_bib0160","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00345-010-0546-2","article-title":"Treatment and outcome in muscle invasive bladder cancer: a population-based survey","volume":"28","author":"Leliveld","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0165","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.05.005_bib0170","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.canrad.2024.05.005_bib0175","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) meta-analysis collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0180","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.urology.2020.08.038","article-title":"Comparison of major complications at 30 and 90 days following radical cystectomy","volume":"148","author":"Knorr","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.canrad.2024.05.005_bib0185","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1007\/s11136-020-02544-z","article-title":"Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer: an umbrella review","volume":"29","author":"Rammant","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.canrad.2024.05.005_bib0190","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.clon.2014.05.007","article-title":"Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study","volume":"26","author":"Booth","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.canrad.2024.05.005_bib0195","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.juro.2018.06.001","article-title":"Effectiveness of transurethral resection plus systemic chemotherapy as definitive treatment for muscle invasive bladder cancer in population level data","volume":"200","author":"Audenet","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0200","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2024.05.005_bib0205","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0210","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0215","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0220","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bju.14109","article-title":"Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer","volume":"121","author":"Ritch","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.canrad.2024.05.005_bib0225","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.critrevonc.2015.04.006","article-title":"Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials","volume":"95","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0230","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0235","doi-asserted-by":"crossref","first-page":"564779","DOI":"10.3389\/fonc.2020.564779","article-title":"Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: a meta-analysis","volume":"10","author":"Ding","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0240","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0245","first-page":"43","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.canrad.2024.05.005_bib0250","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving trimodality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0255","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0260","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1002\/cncr.30900","article-title":"Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer","volume":"123","author":"Cahn","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2024.05.005_bib0265","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/0284186X.2020.1723164","article-title":"Impact of age on bladder cancer management practices: a general population study","volume":"59","author":"Plouvier","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0270","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00005392-200101000-00014","article-title":"Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group study","volume":"165","author":"Hussain","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0275","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/djq121","article-title":"Use of radical cystectomy for patients with invasive bladder cancer","volume":"102","author":"Gore","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2024.05.005_bib0280","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.05.005_bib0285","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41416-018-0084-z","article-title":"Health-related quality of life after treatment for bladder cancer in England","volume":"118","author":"Mason","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2024.05.005_bib0290","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:16:55Z","timestamp":1733055415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321824001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1278321824001690"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2024.05.005","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}